PE20011030A1 - Combinaciones farmaceuticas que comprenden tegaserod y omeprazol - Google Patents
Combinaciones farmaceuticas que comprenden tegaserod y omeprazolInfo
- Publication number
- PE20011030A1 PE20011030A1 PE2000001312A PE0013122000A PE20011030A1 PE 20011030 A1 PE20011030 A1 PE 20011030A1 PE 2000001312 A PE2000001312 A PE 2000001312A PE 0013122000 A PE0013122000 A PE 0013122000A PE 20011030 A1 PE20011030 A1 PE 20011030A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halogen
- antagonists
- receptor
- anodycle
- Prior art date
Links
- IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 title abstract 2
- 229960002876 tegaserod Drugs 0.000 title abstract 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title 1
- 229960000381 omeprazole Drugs 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229940044551 receptor antagonist Drugs 0.000 abstract 3
- 239000002464 receptor antagonist Substances 0.000 abstract 3
- 108091005482 5-HT4 receptors Proteins 0.000 abstract 2
- 150000003973 alkyl amines Chemical class 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 108091005477 5-HT3 receptors Proteins 0.000 abstract 1
- 102000035037 5-HT3 receptors Human genes 0.000 abstract 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical class C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 abstract 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical class [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 abstract 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 abstract 1
- 229940127504 Somatostatin Receptor Agonists Drugs 0.000 abstract 1
- 230000003187 abdominal effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
- SFDJOSRHYKHMOK-UHFFFAOYSA-N nitramide Chemical compound N[N+]([O-])=O SFDJOSRHYKHMOK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004031 partial agonist Substances 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMBINACION QUE COMPRENDE: a) UN COMPUESTO AGONISTA PARCIAL DEL RECEPTOR 5-HT4 DE FORMULA I; DONDE R1 ES H, ALQUILO C1-C6, CARBONILO, BENZOILO, FENILALQUILCARBONILO C1-C4, R5 ES H, HALOGENO, ALQUILO C1-C6, OH, NITRO, AMINO, ALQUILAMINO C1-C6, ALQUILCARBONILAMINO, SO2NRaRb ; Ra Y Rb SON H, ALQUILO C1-C6, CIANO, TRIMETILSILILO, ALQUILO C1-C6, ENTRE OTROS; R6 ES H, CUANDO R5 ES OH R6 ES H, HALOGENO; Z ES -CR4=; R4 ES H, HALOGENO, OH, ALQUILO C1-C6; R7 ES H, HALOGENO, ALQUILO C1-C6; X-Y ES -CR8=N- o -CH(R8)-NH-; R8 ES H, ALQUILO C1-C6; B ES UN GRUPO a; n ES 1-2; A1 ES C=O, CH2; X1 ES S; NR11; R11 ES H, ALQUILO C1-C6 ENTRE OTROS; TAL COMO TEGASEROD (3-(5-METOXI-1H-INDOL-3-IL-METILEN)-N-PENTILCARBAZIMIDAMIDA); b) UN COAGENTE SELECCIONADO A PARTIR DE ANTAGONISTAS DEL RECEPTOR 5-HT3, AGONISTAS O ANTAGONISTAS DEL RECEPTOR 5-HT4, AGONISTAS DEL RECEPTOR DE SOMATOSTATINA, ANTAGONISTAS DEL RECEPTOR HISTAMINA H2, INHIBIDORES DE BOMBA DE PROTONES, AGENTES ANTIESPASMODICOS Y ANTIMUSCARINICOS, ANTIDEPRESIVOS TRICICLICOS, ANTAGONISTAS DEL RECEPTOR COLECISTOQUININA, ENTRE OTROS. LA COMBINACION PUEDE SER UTIL PARA REGULAR, ESTABILIZAR, NORMALIZAR LA MOVILIDAD GASTROINTESTINAL ALTERADA, DESORDENES ABDOMINALES
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45838899A | 1999-12-10 | 1999-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20011030A1 true PE20011030A1 (es) | 2001-10-31 |
Family
ID=23820591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2000001312A PE20011030A1 (es) | 1999-12-10 | 2000-12-07 | Combinaciones farmaceuticas que comprenden tegaserod y omeprazol |
Country Status (30)
| Country | Link |
|---|---|
| EP (3) | EP1286668B1 (es) |
| JP (1) | JP2003523324A (es) |
| KR (1) | KR100765579B1 (es) |
| CN (2) | CN1875966A (es) |
| AR (1) | AR026916A1 (es) |
| AT (1) | ATE293971T1 (es) |
| AU (2) | AU778869B2 (es) |
| BR (1) | BR0016275A (es) |
| CA (1) | CA2388959A1 (es) |
| CO (1) | CO5261535A1 (es) |
| CZ (1) | CZ300690B6 (es) |
| DE (1) | DE60019814T2 (es) |
| DK (1) | DK1286668T3 (es) |
| ES (1) | ES2240229T3 (es) |
| HU (1) | HUP0301122A3 (es) |
| IL (2) | IL149496A0 (es) |
| MX (1) | MXPA02005695A (es) |
| MY (1) | MY133423A (es) |
| NO (1) | NO20022680L (es) |
| NZ (2) | NZ566800A (es) |
| PE (1) | PE20011030A1 (es) |
| PL (1) | PL202201B1 (es) |
| PT (1) | PT1286668E (es) |
| RU (1) | RU2264215C2 (es) |
| SG (1) | SG152025A1 (es) |
| SK (1) | SK8062002A3 (es) |
| TR (1) | TR200402293T2 (es) |
| TW (1) | TWI263496B (es) |
| WO (1) | WO2001041748A2 (es) |
| ZA (1) | ZA200204493B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003533482A (ja) * | 2000-05-18 | 2003-11-11 | グラクソ グループ リミテッド | 機能性消化不良の治療方法 |
| GB0209481D0 (en) * | 2002-04-24 | 2002-06-05 | Novartis Ag | Organic compounds |
| MXPA05007379A (es) | 2003-01-13 | 2006-02-10 | Dynogen Pharmaceuticals Inc | Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos. |
| GB0307440D0 (en) * | 2003-03-31 | 2003-05-07 | Novartis Ag | Organic compounds |
| RS20050868A (sr) * | 2003-05-27 | 2007-08-03 | Altana Pharma Ag., | Farmaceutske kombinacije inhibotora protonske pumpe i jedinjenje koje modifikuje gastrointestinalni motilitet |
| US20050090554A1 (en) * | 2003-09-12 | 2005-04-28 | John Devane | Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists |
| US7820690B2 (en) | 2004-03-19 | 2010-10-26 | Solvay Pharmaceuticals Gmbh | Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist |
| CA2573209A1 (en) * | 2004-07-14 | 2006-01-19 | Novartis Ag | Combination of dpp-iv inhibitors and compounds modulating 5-ht3 and/or 5-ht4 receptors |
| KR20070107016A (ko) * | 2005-01-31 | 2007-11-06 | 노파르티스 아게 | 양성자 펌프 억제제에 의해 유발될 수 있는 위 배출 지연을치료하기 위한 5-ｈｔ4 효능제의 용도 |
| GB0506800D0 (en) * | 2005-04-04 | 2005-05-11 | Merck Sharp & Dohme | New uses |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8354434B2 (en) | 2006-01-30 | 2013-01-15 | Purdue Pharma L.P. | Cyclourea compounds as calcium channel blockers |
| AU2007257652A1 (en) * | 2006-06-15 | 2007-12-21 | Novartis Ag | Compositions comprising tegaserod alone or in combination with a proton pump inhibitor for treating or preventing gastric injury |
| ES2604943T3 (es) | 2007-02-09 | 2017-03-10 | Ocera Therapeutics, Inc. | Moduladores macrocíclicos del receptor de la grelina y procedimientos de uso de los mismos |
| WO2009064458A2 (en) | 2007-11-13 | 2009-05-22 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| US20090143343A1 (en) | 2007-11-13 | 2009-06-04 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| SG11201810509PA (en) | 2016-06-20 | 2018-12-28 | Kymab Ltd | Anti-pd-l1 antibodies |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
| US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| EP3728314A1 (en) | 2017-12-19 | 2020-10-28 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| US20220396623A1 (en) | 2021-05-18 | 2022-12-15 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| US20250340641A1 (en) | 2022-05-18 | 2025-11-06 | Kymab Limited | Uses of anti-icos antibodies |
| FR3144752A1 (fr) | 2023-01-10 | 2024-07-12 | Song Huang | Utilisation de polysulfate de pentosane pour le traitement de la toux seche |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5362756A (en) * | 1989-02-20 | 1994-11-08 | Riviere Pierre J M | Use of fedotozine in the treatment of functional states of intestinal obstructions |
| HUT64023A (en) * | 1991-03-22 | 1993-11-29 | Sandoz Ag | Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds |
| ES2121984T3 (es) * | 1991-12-21 | 1998-12-16 | Smithkline Beecham Plc | Uso de antagonistas de 5-ht4 para la fabricacion de un medicamento para el tratamiento de la incontinencia urinaria. |
| GB9214184D0 (en) * | 1992-07-03 | 1992-08-12 | Smithkline Beecham Plc | Pharmaceuticals |
| NZ295259A (en) * | 1994-11-21 | 1998-05-27 | Dainippon Pharmaceutical Co | N-[1-ethyl(or cyclopropylmethyl)azapin-, azocin- or azonin-3-yl] 6-methoxy-1h-benzotriazole-5-carboxamide derivatives |
| US5919760A (en) * | 1996-04-12 | 1999-07-06 | Intensive Narcotic Detoxification Centers Of America, Llc | Method for treating acute and severe diarrhea |
| US6156771A (en) * | 1997-08-28 | 2000-12-05 | Rubin; Walter | Method for alleviation of lower gastrointestinal disorders in a human patient |
| GB9721139D0 (en) * | 1997-10-07 | 1997-12-03 | Glaxo Group Ltd | Medicaments |
-
2000
- 2000-11-20 TW TW089124545A patent/TWI263496B/zh not_active IP Right Cessation
- 2000-12-06 CO CO00093154A patent/CO5261535A1/es not_active Application Discontinuation
- 2000-12-07 AR ARP000106516A patent/AR026916A1/es unknown
- 2000-12-07 PE PE2000001312A patent/PE20011030A1/es not_active Application Discontinuation
- 2000-12-08 MY MYPI20005769A patent/MY133423A/en unknown
- 2000-12-08 BR BR0016275-2A patent/BR0016275A/pt not_active Application Discontinuation
- 2000-12-08 EP EP00989967A patent/EP1286668B1/en not_active Expired - Lifetime
- 2000-12-08 CA CA002388959A patent/CA2388959A1/en not_active Abandoned
- 2000-12-08 ES ES00989967T patent/ES2240229T3/es not_active Expired - Lifetime
- 2000-12-08 AU AU26728/01A patent/AU778869B2/en not_active Ceased
- 2000-12-08 NZ NZ566800A patent/NZ566800A/en unknown
- 2000-12-08 CN CNA2006100918377A patent/CN1875966A/zh active Pending
- 2000-12-08 PL PL355663A patent/PL202201B1/pl not_active IP Right Cessation
- 2000-12-08 CN CNB008168814A patent/CN1310644C/zh not_active Expired - Fee Related
- 2000-12-08 DE DE60019814T patent/DE60019814T2/de not_active Expired - Lifetime
- 2000-12-08 PT PT00989967T patent/PT1286668E/pt unknown
- 2000-12-08 HU HU0301122A patent/HUP0301122A3/hu unknown
- 2000-12-08 RU RU2002118316/15A patent/RU2264215C2/ru not_active IP Right Cessation
- 2000-12-08 SK SK806-2002A patent/SK8062002A3/sk unknown
- 2000-12-08 MX MXPA02005695A patent/MXPA02005695A/es active IP Right Grant
- 2000-12-08 EP EP04020247A patent/EP1488788A1/en not_active Withdrawn
- 2000-12-08 CZ CZ20021967A patent/CZ300690B6/cs not_active IP Right Cessation
- 2000-12-08 KR KR1020027007332A patent/KR100765579B1/ko not_active Expired - Fee Related
- 2000-12-08 AT AT00989967T patent/ATE293971T1/de not_active IP Right Cessation
- 2000-12-08 SG SG200404415-2A patent/SG152025A1/en unknown
- 2000-12-08 WO PCT/EP2000/012420 patent/WO2001041748A2/en not_active Ceased
- 2000-12-08 TR TR2004/02293T patent/TR200402293T2/xx unknown
- 2000-12-08 DK DK00989967T patent/DK1286668T3/da active
- 2000-12-08 IL IL14949600A patent/IL149496A0/xx unknown
- 2000-12-08 JP JP2001543093A patent/JP2003523324A/ja active Pending
- 2000-12-08 NZ NZ531489A patent/NZ531489A/en unknown
-
2002
- 2002-05-06 IL IL149496A patent/IL149496A/en not_active IP Right Cessation
- 2002-06-05 ZA ZA200204493A patent/ZA200204493B/xx unknown
- 2002-06-06 NO NO20022680A patent/NO20022680L/no not_active Application Discontinuation
-
2004
- 2004-08-26 EP EP07122308A patent/EP1913944A1/en not_active Withdrawn
-
2005
- 2005-02-22 AU AU2005200797A patent/AU2005200797B2/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20011030A1 (es) | Combinaciones farmaceuticas que comprenden tegaserod y omeprazol | |
| PE20010854A1 (es) | USO DE DERIVADOS DE PIRIMIDINA 4 SUSTITUIDOS COMO ANTAGONISTAS DE LOS RECEPTORES DE GLUTAMATO mGluR1 | |
| PE20040935A1 (es) | Analogos de 2-quinazolina sustituida-4-ilamina como moduladores de los receptores de capsaicina | |
| PE20060401A1 (es) | Derivados de n-(2-bencil)-2-fenil-butanamidas y propanamidas como moduladores del receptor de androgeno | |
| PE20050525A1 (es) | Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1 | |
| PE20011265A1 (es) | Novedosos derivados diamino sustituidos | |
| PE20021005A1 (es) | Quinazolinas como inhibidores de mmp-13 | |
| PE20030471A1 (es) | Compuesto de imidazopiridin como moduladores del receptor 5-ht4 | |
| NO20050429L (no) | Substituert kinolin-CCR5-reseptorantagonister | |
| ES2161231T3 (es) | Compuestos heterociclicos como antagonistas de bradiquinina. | |
| PE20050193A1 (es) | Compuestos heterociclicos utiles como activadores de nurr-1 | |
| PE20020720A1 (es) | Derivados benzimidazol y piridilimidazol como ligandos para receptores gabaa | |
| PE20040758A1 (es) | Compuestos 3-aminopirazoles n-sustituidos como inhibidores de la enzima tirosin-quinasa asociada al receptor pdgf y procedimientos para su preparacion | |
| PE20021094A1 (es) | Derivados de ciclohexano-1,4-diamina sustituidos | |
| DK1173433T3 (da) | Cyanopyrroler som progesteronreceptoragonister | |
| ATE401066T1 (de) | Methoden zur behandlung der essstörungen | |
| ATE325119T1 (de) | 3-substituierte oxindol-beta-3-agonisten | |
| EA200301073A1 (ru) | N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора | |
| PE44297A1 (es) | Compuestos de 3-dimetilamino-2-metilfenilimino imidazolidina con actividad como agonistas de o1l para el tratamiento de la incontinencia urinaria | |
| PE20011114A1 (es) | Decahidro-isoquinolinas | |
| AR037065A1 (es) | Una composicion farmaceutica en base a bloqueadores de receptores 5ht3 y 5ht4, inhibidores de la bomba de protones y antagonistas de receptores de h2, util para tratar los desordenes gastrointestinales | |
| PE20060689A1 (es) | Derivados de sulfonamidas como antagonistas de receptores orexina 2 | |
| PE20060604A1 (es) | Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion | |
| PE20091243A1 (es) | Compuesto heterociclico fusionado | |
| PE20050420A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |